Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II--The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Context.--The world of oncology has changed dramatically in the past few years with the introduction of checkpoint inhibitors and immunotherapy. The promising findings of a small, phase 2 clinical trial that led to the US Food and Drug Administration breakthrough designation and approval of the anti...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 142; no. 1; pp. 26 - 35 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial research systematic review tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Jan2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |